Correlations of Insulin Resistance and Serum Testosterone Levels with LH:FSH Ratio and Oxidative Stress in Women with Functional Ovarian Hyperandrogenism

Indian Journal of Clinical Biochemistry

Volumn 30, Issue 3, 2015, Pages 345-350

  Suresh, S ^a   Vijayakumar, T ^b  

^a MAHATMA GANDHI UNIVERSITY   (India)

^b Educare Institute of Dental Sciences   (India)

Author keywords

Functional ovarian hyperandrogenism; Insulin resistance; LH:FSH ratio; Oxidative stress; Polycystic ovary syndrome; Total and free testosterone

Indexed keywords

ANDROGEN; ANTIOXIDANT; CATALASE; FOLLITROPIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INSULIN; LUTEINIZING HORMONE; MALONALDEHYDE; OXIDIZING AGENT; SUPEROXIDE DISMUTASE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; FOLLITROPIN BLOOD LEVEL; FUNCTIONAL OVARIAN HYPERANDROGENISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREDICTIVE VALUE; TESTOSTERONE BLOOD LEVEL;

EID: 84931003688     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-014-0447-z     Document Type: Article

References (31)

1. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671–83.
2. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril. 2005;83:1343–6.
3. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97.
4. Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2010;93:1938–41.
5. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122:42–52.
6. Kauffman RP, Baker VM, DiMarino P, Castracane VD. Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. Fertil Steril. 2006;85:1010–6.
7. Siklar Ζ, Ocal G, Adiyaman P, Ergur A, Berberoglu M. Functional ovarian hyperandrogenism and polycystic ovary syndrome in prepubertal girls with obesity and/or premature pubarche. J Pediatr Endocrinol Metab. 2007;20:475–81.
8. Galluzzo A, Amato MC, Giordano C. Insulin resistance and polycystic ovary syndrome. Nutr Metab Cardiovasc Dis. 2008;18:511–8.
9. Nisenblat V, Norman RJ. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2009;16:224–31.
10. Sakumoto T, Tokunaga Y, Tanaka H, Nohara M, Motegi E, Shinkawa T, et al. Insulin resistance/hyperinsulinemia and reproductive disorders in infertile women. Reprod Med Biol. 2010;9:185–90.
11. Baptiste CG, Battista MC, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122:42–52.
12. Gambineri A, Patton L, Prontera O, Fanelli F, Ciampaglia W, Cognigni GE, Pagotto U, Pasquali R. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome. J Endocrinol Investig. 2011;34:685–91.
13. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;14:3–28.
14. Gonzalez F, Rote NS, Minium J, Kirwan JP. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:336–40.
15. Verit FF, Erel O. Oxidative stress in non-obese women with polycystic ovary syndrome: correlations with endocrine and screening parameters. Gynecol Obstet Investig. 2008;65:233–9.
16. Kuscu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009;88:612–7.
17. Kandasamy S, Sivagamasundari RI, Bupathy A, Sethubathy S, Gobal V. Evaluation of insulin resistance and oxidative stress in obese patients with polycystic ovary syndrome. Int J Appl Biol Pharm Technol. 2010;1:391–7.
18. Kurdoglu Z, Ozkol H, Tuluce Y, Koyuncu I. Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome. J Endocrinol Investig. 2011;26:134–42.
19. Insler V, Lunenfeld B. Polycystic ovarian disease. In: Insler V, Lunenfeld B, editors. Infertility—male and female. 2nd ed. London: Churchill Livingstone; 1993. p. 661–75.
20. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7:219–31.
21. Burtis CA, Ashwood ER, Bruns DE. Tietz text book of clinical chemistry and molecular diagnostics. 4th ed. Philadelphia: WB Saunders; 2004. p. 96–405.
22. Clark PM. Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem. 1999;36:541–64.
23. Whitley RJ, Meikle AW, Watts NB. Endocrinology, part VI: adrenocortical steroids. In: Burtis CA, Ashwood ER, editors. Textbook of clinical chemistry. 4th ed. Philadelphia: WB Saunders; 2004. p. 508–31.
24. Wartofsky L, Handelsman DJ. Standardization of hormonal assays for the 21st century. J Clin Endocrinol Metab. 2010;95:4971–5143.
25. Wheeler MJ. The determination of bio-available testosterone. Ann Clin Biochem. 1995;32:345–51.
26. Abuja PM, Albertini R. Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta. 2001;306:1–17.
27. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi Y, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care. 1999;22:818–22.
28. Mahajan BK. Methods in biostatistics for medical students and research workers. 7th ed. New Delhi: Jaypee Brothers; 2010. pp. 80–194.
29. Paduch DA, Brannigan RE, Fuchs EF, Kim ED, Marmar JL, Sandlow JI. The Laboratory Diagnosis of Testosterone Deficiency, Am Urol Assoc Educ Res; 2013:7–12.
30. Azziz R, Carmina E, Dewailly D, Kandarakis DE, Morreale EHF, Futterweit W, et al. The androgen excess and PCOS society criteria for the polycystic ovary syndrome. Fertil Steril. 2009;91:456–88.
31. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.